Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017458992> ?p ?o ?g. }
- W2017458992 endingPage "79" @default.
- W2017458992 startingPage "65" @default.
- W2017458992 abstract "Introduction: The combination of two nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) and a third agent from another antiretroviral class is currently recommended for initial antiretroviral therapy. In general, N(t)RTIs remain relevant in subsequent regimens. There are currently six nucleoside reverse transcriptase inhibitors and one nucleotide reverse transcriptase inhibitor drug entities available, and several formulations that include two or more N(t)RTIs in a fixed-dose combination. These entities have heterogeneous pharmacological and clinical properties. Accordingly, toxicity, pill burden, dosing frequency, potential drug–drug interaction, preexisting antiretroviral drug resistance and comorbid conditions should be considered when constructing a regimen. This approach is critical in order to optimize virologic efficacy and clinical outcomes. Areas covered: This article reviews N(t)RTI combinations used in the treatment of HIV-infected adults. The pharmacological properties of each N(t)RTI, and the clinical trials that have influenced treatment guidelines are discussed. Expert opinion: It is likely that N(t)RTIs will continue to dominate the global landscape of HIV treatment and prevention, despite emerging interest in N(t)RTI-free combination therapy. Clinical domains where only few alternatives to N(t)RTIs exist include treatment of HIV/HBV coinfection and HIV-2. There is a need for novel N(t)RTIs with enhanced safety and resistance profiles compared with current N(t)RTIs." @default.
- W2017458992 created "2016-06-24" @default.
- W2017458992 creator A5015872083 @default.
- W2017458992 creator A5041036157 @default.
- W2017458992 creator A5074187192 @default.
- W2017458992 creator A5089278105 @default.
- W2017458992 date "2011-12-09" @default.
- W2017458992 modified "2023-10-16" @default.
- W2017458992 title "Combination Nucleoside/Nucleotide Reverse Transcriptase Inhibitors for Treatment of HIV Infection" @default.
- W2017458992 cites W1426208733 @default.
- W2017458992 cites W1550604532 @default.
- W2017458992 cites W1724881152 @default.
- W2017458992 cites W1965370152 @default.
- W2017458992 cites W1968789632 @default.
- W2017458992 cites W1971987445 @default.
- W2017458992 cites W1978696458 @default.
- W2017458992 cites W1978724449 @default.
- W2017458992 cites W1979035566 @default.
- W2017458992 cites W1979116787 @default.
- W2017458992 cites W1980463219 @default.
- W2017458992 cites W1981280862 @default.
- W2017458992 cites W1985698850 @default.
- W2017458992 cites W1986185361 @default.
- W2017458992 cites W1990951677 @default.
- W2017458992 cites W1991476347 @default.
- W2017458992 cites W1996313031 @default.
- W2017458992 cites W1998204576 @default.
- W2017458992 cites W2002521249 @default.
- W2017458992 cites W2004813828 @default.
- W2017458992 cites W2007535230 @default.
- W2017458992 cites W2013129339 @default.
- W2017458992 cites W2014533894 @default.
- W2017458992 cites W2015796602 @default.
- W2017458992 cites W2016257631 @default.
- W2017458992 cites W2016842950 @default.
- W2017458992 cites W2017480044 @default.
- W2017458992 cites W202332265 @default.
- W2017458992 cites W2026323517 @default.
- W2017458992 cites W2028873388 @default.
- W2017458992 cites W2029174775 @default.
- W2017458992 cites W2030384645 @default.
- W2017458992 cites W2031845569 @default.
- W2017458992 cites W2032026161 @default.
- W2017458992 cites W2033101026 @default.
- W2017458992 cites W2034727191 @default.
- W2017458992 cites W2041314794 @default.
- W2017458992 cites W2049287879 @default.
- W2017458992 cites W2055922999 @default.
- W2017458992 cites W2056779298 @default.
- W2017458992 cites W2057392755 @default.
- W2017458992 cites W2058712798 @default.
- W2017458992 cites W2061857819 @default.
- W2017458992 cites W2063546567 @default.
- W2017458992 cites W2067043659 @default.
- W2017458992 cites W2067346978 @default.
- W2017458992 cites W2068616720 @default.
- W2017458992 cites W2069455040 @default.
- W2017458992 cites W2086785150 @default.
- W2017458992 cites W2086893453 @default.
- W2017458992 cites W2088089484 @default.
- W2017458992 cites W2089493687 @default.
- W2017458992 cites W2093984759 @default.
- W2017458992 cites W2095273553 @default.
- W2017458992 cites W2096070610 @default.
- W2017458992 cites W2096494132 @default.
- W2017458992 cites W2098330191 @default.
- W2017458992 cites W2099736382 @default.
- W2017458992 cites W2100157044 @default.
- W2017458992 cites W2101610242 @default.
- W2017458992 cites W2102136130 @default.
- W2017458992 cites W2103920597 @default.
- W2017458992 cites W2107901271 @default.
- W2017458992 cites W2108978066 @default.
- W2017458992 cites W2109159474 @default.
- W2017458992 cites W2109213931 @default.
- W2017458992 cites W2110937893 @default.
- W2017458992 cites W2112687747 @default.
- W2017458992 cites W2113092110 @default.
- W2017458992 cites W2114281928 @default.
- W2017458992 cites W2117261241 @default.
- W2017458992 cites W2119433625 @default.
- W2017458992 cites W2122939659 @default.
- W2017458992 cites W2126312216 @default.
- W2017458992 cites W2127069469 @default.
- W2017458992 cites W2127518061 @default.
- W2017458992 cites W2127578660 @default.
- W2017458992 cites W2128469241 @default.
- W2017458992 cites W2131730357 @default.
- W2017458992 cites W2140055542 @default.
- W2017458992 cites W2141776019 @default.
- W2017458992 cites W2143161491 @default.
- W2017458992 cites W2144095981 @default.
- W2017458992 cites W2144658061 @default.
- W2017458992 cites W2144920286 @default.
- W2017458992 cites W2146634980 @default.
- W2017458992 cites W2148535109 @default.
- W2017458992 cites W2154935934 @default.
- W2017458992 cites W2158715155 @default.